Market Overview

Goldman Sachs Downgrades Aetna To Neutral

Share:
Related AET
CVS Growth May Have Weakened, But Credit Suisse Still Sees Catalysts
Healthcare Shocker
ObamaCare Mandates Are Dead — Even If Hillary Wins (Investor's Business Daily)

Analysts at Goldman Sachs downgraded Aetna (NYSE: AET) from Buy to Neutral.

The target price for Aetna has been lowered from $94.00 to $88.00.

Aetna shares have surged 24.00% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Aetna's shares dropped 0.61% to $77.84 in pre-market trading.

Latest Ratings for AET

DateFirmActionFromTo
Sep 2016Evercore ISI GroupInitiates Coverage onBuy
Jul 2016Wolfe ResearchDowngradesOutperformPeer Perform
Jun 2016BernsteinInitiates Coverage onOutperform

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Goldman SachsDowngrades Analyst Ratings

 

Related Articles (AET)

View Comments and Join the Discussion!